Clinical trials: ALS - Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)
GM604 is an endogenous human embryonic stage neural regulatory and signaling peptide that controls the development, monitoring and correction of the human nervous system.
- Trial name
- GALS (NCT01854294)
- Testing
- GM604
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Genervon Biopharmaceuticals, LLC
ALS
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS) based on the change in ALS Functional Rating Scale- Revised (ALSFRS-R) score from baseline up to…
- Trial name
- NCT04569084
- Testing
- MT-1186
- Where
- 95 sites in United States, Canada and 5 more
- Volunteers
- 384 people
- Sponsor
- Shionogi
Upper Extremity Impairments, Cerebral Palsy (CP)
Obi Medical Robot: Evaluating Effectiveness Related to Usability
This mixed-methods usability study evaluates the effectiveness of the Obi Gen 3 robotic feeding device in meeting user needs among providers, caregivers, and patients.
- Conditions
- Upper Extremity Impairments, Cerebral Palsy (CP), ALS - Amyotrophic Lateral Sclerosis, Rett Syndrome
- Trial name
- NCT07151950
- Testing
- One-week trial of Obi Medical device, which provides robotic assistance with feeding to persons with upper extremity impairments who are unable to self-feed in the traditional manner using utensils
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Desin LLC
Amyotrophic Lateral Sclerosis
RT001 in Amyotrophic Lateral Sclerosis
RT001-014 is a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects with Amyotrophic Lateral Sclerosis
- Trial name
- NCT04762589
- Testing
- RT001
- Where
- 4 sites in Estonia, Latvia and 2 more
- Volunteers
- 43 people
- Sponsor
- Biojiva LLC
ALS, FTD
Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and PD of intrathecal (IT) WVE-004 in adult patients with C9orf72-associated ALS or FTD.
- Trial name
- FOCUS-C9 (NCT04931862)
- Testing
- WVE-004
- Where
- 17 sites in Australia, Belgium and 6 more
- Volunteers
- 35 people
- Sponsor
- Wave Life Sciences USA, Inc.
Amyotrophic Lateral Sclerosis
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS
The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS
- Trial name
- NCT05633459
- Testing
- Multiple ascending doses of QRL-201, QRL-201
- Where
- 15 sites in Belgium, Canada and 4 more
- Volunteers
- 69 people
- Sponsor
- QurAlis Corporation
Amyotrophic Lateral Sclerosis, Lou Gehrig Disease
MRG-001 in Patients With Amyotrophic Lateral Sclerosis
The proposed study is an Open-Label, Single-Dose Study to Assess the Safety, and Pharmacodynamics (PD) signals of MRG-001 in Patients with Amyotrophic Lateral Sclerosis (ALS).
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Motor Neuron Disease, Motor Neuron Atrophy
- Trial name
- NCT06315608
- Testing
- MRG-001
- Volunteers
- 10 people
- Sponsor
- MedRegen LLC
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis
The purpose of this study is to investigate the safety and tolerability of intrathecal riluzole in adults with amyotrophic lateral sclerosis.
- Trial name
- NCT07093268
- Testing
- Intrathecal Riluzole
- Where
- 2 sites in Australia
- Volunteers
- 10 people
- Sponsor
- Brain Trust Bio
Amyotrophic Lateral Sclerosis
Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial
A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS) who have completed the ORARIALS-01 trial.
- Trial name
- NCT03836716
- Testing
- Arimoclomol
- Where
- 23 sites in United States, Belgium and 9 more
- Volunteers
- 120 people
- Sponsor
- ZevraDenmark
Amyotrophic Lateral Sclerosis (ALS)
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This is a Phase 3, international, multicenter, open-label, long-term extension study. The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral…
- Trial name
- NCT04577404
- Testing
- MT-1186
- Where
- 44 sites in United States, Canada and 4 more
- Volunteers
- 124 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis (ALS)
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
The primary objective of the study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip infusion once a day in the patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores…
- Trial name
- NCT01492686
- Testing
- MCI-186, MCI-186 in open label phase
- Where
- Japan
- Volunteers
- 137 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis
An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis
This is an open label safety and tolerability continuation study of intracerebroventricular administration of sNN0029, containing the growth factor VEGF165, in patients with amyotrophic lateral sclerosis that have previously…
- Trial name
- NCT01384162
- Testing
- sNN0029
- Where
- Belgium
- Volunteers
- 15 people
- Sponsor
- Newron Sweden AB
Amyotrophic Lateral Sclerosis (ALS)
Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases
An open, multi- center phase Ⅰ clinical study evaluating the safety and efficacy of autologous human polyclonal regulatory T cell injection (NP001 cell injection) in patients with Neurodegenerative diseases (ALS).
- Trial name
- NCT06671236
- Testing
- Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Novabio Therapeutics
Amyotrophic Lateral Sclerosis
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label…
- Trial name
- COMBAT-ALS (NCT04057898)
- Testing
- MN-166
- Where
- 16 sites in United States, Canada
- Volunteers
- 234 people
- Sponsor
- MediciNova
Alzheimer's Disease, Multiple Sclerosis
A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies.
- Conditions
- Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease
- Trial name
- NCT01592552
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Amyotrophic Lateral Sclerosis
A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study was to assess the effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on respiratory function and other measures of skeletal muscle function in patients with ALS.
- Trial name
- FORTITUDE-ALS (NCT03160898)
- Testing
- Reldesemtiv
- Where
- 64 sites in United States, Australia and 4 more
- Volunteers
- 458 people
- Sponsor
- Cytokinetics
Parkinson Disease Psychosis, Amyotrophic Lateral Sclerosis (ALS)
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of oral doses of FB418 in healthy adult subjects and healthy elderly subjects.
- Trial name
- NCT05995782
- Testing
- FB418
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- 1ST Biotherapeutics, Inc.
Amyotrophic Lateral Sclerosis
Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS
This study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS.
- Trial name
- CARDINALS (NCT05349721)
- Testing
- PTC857
- Where
- 55 sites in United States, Argentina and 11 more
- Volunteers
- 336 people
- Sponsor
- PTC Therapeutics
Amyotrophic Lateral Sclerosis
Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)
The objective of this trial was to assess the efficacy, safety, and PK/PD effects of CNM-Au8 as a disease-modifying agent for the treatment of ALS by utilizing electrophysiological measures to detect preservation of motor neuron…
- Trial name
- RESCUE-ALS (NCT04098406)
- Testing
- CNM-Au8
- Where
- 2 sites in Australia
- Volunteers
- 45 people
- Sponsor
- Clene Nanomedicine
Amyotrophic Lateral Sclerosis, Renal Insufficiency
Dexpramipexole Renal PK Study
This is a multicenter, open-label, single-dose, PK and safety study in subjects with various stages of renal impairment.
- Trial name
- NCT01424176
- Testing
- Dexpramipexole (dose 1), Dexpramipexole (dose 2)
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Knopp Biosciences